4-amylcinnamoylanthranilic-acid has been researched along with Reperfusion-Injury* in 2 studies
2 other study(ies) available for 4-amylcinnamoylanthranilic-acid and Reperfusion-Injury
| Article | Year |
|---|---|
The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.
The transient receptor potential melastatin 2 (TRPM2) channel is associated with ischemia/reperfusion injury, inflammation, cancer, and neurodegenerative diseases. However, the limit of specific inhibitors impedes the development of TRPM2-targeted therapeutic agents. To discover more potent and selective TRPM2 inhibitors, 59 Topics: Animals; Cell Line, Tumor; Cinnamates; Glucose; HEK293 Cells; Humans; Infarction, Middle Cerebral Artery; Male; Mice, Inbred C57BL; Molecular Structure; Neuroprotective Agents; ortho-Aminobenzoates; Oxygen; Reperfusion Injury; Structure-Activity Relationship; TRPM Cation Channels | 2021 |
Protective effect of N-(p-amylcinnamoyl) anthranilic acid, phospholipase A
Topics: Acute Kidney Injury; Animals; Antioxidants; Blood Urea Nitrogen; Caspase 3; Catalase; Cell Adhesion Molecules; Cinnamates; Creatinine; Cystatin C; Gene Expression Regulation; Interleukin-18; Kidney; Lipocalin-2; Male; Malondialdehyde; ortho-Aminobenzoates; Oxidative Stress; Phospholipase A2 Inhibitors; Phospholipases A2; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Reperfusion Injury; TRPM Cation Channels | 2019 |